Citigroup Raises Establishment Labs Price Target Following Robust Q1 Revenue Growth

Key Facts

1Citigroup maintained a Neutral rating on Establishment Labs while raising the price target from $65 to $76.

2The company reported Q1 revenue of $59.9 million, representing a 44.7% year-over-year increase.

3The company achieved a positive adjusted EBITDA of $1.2 million and narrowed its quarterly loss to $0.40 per share.

Citigroup has increased its price target for Establishment Labs (ESTA) to $76 from $65, while maintaining a Neutral rating on the stock. The revision follows a strong first-quarter performance where the company reported revenue of $59.9 million, a significant 44.7% increase year-over-year. Notably, the firm achieved a positive adjusted EBITDA of $1.2 million and successfully narrowed its quarterly loss to $0.40 per share. This growth was largely driven by robust sales of Motiva breast implants in the U.S. market. Consequently, the company has raised its full-year guidance, signaling confidence in its operational momentum and expanding footprint within the medical technology sector.